Bengaluru, Sept. 25 -- During Thursday's trading session, shares of one of the leading globally vertically integrated pharmaceutical companies with a focus on R&D to manufacture niche and complex molecules surged nearly 5 percent on BSE, after the company's Board approved the evaluation of agro business demerger.

At 01:42 p.m., the shares of NATCO Pharma Limited were trading at Rs. 848.6 on BSE, as against its previous closing price of Rs. 854.45, with a market cap of Rs. 15,199 crores. The stock has delivered negative returns of over 40 percent in one year, and has fallen by nearly 3 percent in the last one month.

What's the News As per the latest regulatory filings, NATCO Pharma Limited has granted in-principle approval to evaluate th...